Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema

NCT01849159 | Withdrawn Phase 1 DMC

• 2 other identifiers: MSC-HYP-01FMBA-FRCC-MSC-01
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Actively developing stem cells (SCs) transplantation techniques cause natural interest to the problem of regeneration in the lungs. Numerous experimental studies proved the benefits of different types of SCs in experimental models of pulmonary emphysema (PE). G. Zhen et al. have shown that the transplantation of mesenchymal stem cells (MSCs) to rats with papain-induced emphysema leads to their migration into the lungs, differentiation into type 2 alveolocytes, and inhibition of apoptosis and prevention PE. K. Schweitzer et al. have proved the activity of inflammation in the airways, alveolocytes and endothelial cells apoptosis decreased after adipose SCs intravenous administration to mice with emphysema caused by chronic exposure to tobacco smoke or VEGF receptors blockade. The study of E.P. Ingenito et al. found that endobronchial installed MSCs engraft into the alveolar wall and peribronchial interstitium and release integrins, extracellular matrix components (collagen IV, laminin and fibrillin), platelet-derived growth factor receptor and transforming growth factor β2. Our study also found reliable deterrent effect of allogeneic bone marrow MSCs on the development of elastase-induced emphysema in rats at different terms of transplantation. After the success of pilot studies have started clinical trials. Currently, the website http://www. ClinicalTrials.gov reported three studies evaluating the efficacy and safety of MSC transplantation in patients with COPD and emphysema. Two of them have already been completed and the results of the first pilot project published. Authors on the example of 4 patients showed a complete absence of adverse effects, improved quality of life and stability of functional parameters at 12 months after starting treatment One of the problems of MSC transplantation in patients with respiratory failure is an accelerated apoptosis of transplanted cells under the influence of proinflammatory cytokines and oxidative stress. Since it is proved that preconditioning MSCs under hypoxia increases their survival in hypoxic conditions, increases the expression of growth factors and antiinflammatory cytokines, we suppose that MSCs grown in hypoxic medium may have a significant positive effect on the disease.

Conditions

Pulmonary Emphysema

Keywords

Mesenchymal stem cells; Hypoxia; Emphysema

Outcome Measures

Primary Outcomes (1)

• Safety compared with placebo

  Mortality (Baseline and 2 years after procedure) Adverse effects and reactions to the treatment(Baseline and 2 years after procedure). Vital signs (pulse rate, systolic and diastolic arterial blood pressure) (Baseline and 2 years after procedure)

  1 year

Secondary Outcomes (9)

• Change from baseline in the lung tissue density measured by CT-densitometry at6, 12, 24 months

  2 years

• DLCO change from baseline at 6, 12, 24 months

  2 years

• Change from baseline in the functional parameters (FEV1, TLC, RV, FEV1/FVC) at 6,12,18,24 months

  2 years

• Dynamics of the physical capacity (by the 6-min test results)

  2 years

• Dynamics of the blood gas composition (PaO2, PaCO2)

  2 years

Study Arms (2)

MSC group

ACTIVE COMPARATOR

Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year

Biological: Mesenchymal stem cells

Control Group

PLACEBO COMPARATOR

400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year

Other: Reference therapy: 400 mL of 0.9% NaCl solution

Interventions

Mesenchymal stem cells BIOLOGICAL

Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution

MSC group

Reference therapy: 400 mL of 0.9% NaCl solution OTHER

Control Group

Eligibility Criteria

• Age: 35 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• HRCT-confirmed diagnosis of lung emphysema by two independent radiologists
• post-bronchodilator FEV1/FVC ratio \< 0.7
• post-bronchodilator FEV1 % predicted value ≥ 20% and \< 50%
• age 35 and 75 years of, of either sex, and of any race
• current or ex-smoker, with a cigarette smoking history ≥ 10 pack-years

You may not qualify if:

• asthma or other clinically relevant lung disease other than COPD (e.g. restrictive lung diseases, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, or lung cancer)
• α1-Antitrypsin deficiency
• Presence of bullae (more than 10 cm in the diameter)
• active infection within 4 weeks of screening
• significant exacerbation of COPD or has required mechanical ventilation within 4 weeks of screening
• clinically relevant uncontrolled medical condition not associated with COPD
• documented history of uncontrolled heart failure
• pulmonary hypertension due to left heart condition
• Subject has evidence of active malignancy, or prior history of active malignancy
• Subject has a life expectancy of \< 6 months

Sponsors & Collaborators

• Federal Research Clinical Center of Federal Medical & Biological Agency, Russia: lead

Study Sites (1)

Federal Research Clinical Center of Federal Medical and Biological Agency of Russia

Moscow, Moscow Oblast, 115682, Russia

Location

MeSH Terms

Conditions

Pulmonary Emphysema; Hypoxia; Emphysema

Condition Hierarchy (Ancestors)

Pulmonary Disease, Chronic Obstructive; Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Signs and Symptoms, Respiratory; Signs and Symptoms

Study Officials

• Alexander V Averyanov, MD, PhD

  Federal Research Clinical Center of Federal Medical and Biological Agency

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Deputy of Director General of FRCC

Study Record Dates

• First Submitted: April 24, 2013
• First Posted: May 8, 2013
• Study Start: March 1, 2014
• Primary Completion: December 1, 2016
• Study Completion: June 1, 2017
• Last Updated: January 9, 2018

Record last verified: 2018-01

Locations

RU (1)